Publication:

A common antigenic motif recognized by naturally occurring human VH5–51/VL4–1 anti-tau antibodies with distinct functionalities

Loading...
Thumbnail Image

Open/View Files

Date

2018

Journal Title

Journal ISSN

Volume Title

Publisher

BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Apetri, A., R. Crespo, J. Juraszek, G. Pascual, R. Janson, X. Zhu, H. Zhang, et al. 2018. “A common antigenic motif recognized by naturally occurring human VH5–51/VL4–1 anti-tau antibodies with distinct functionalities.” Acta Neuropathologica Communications 6 (1): 43. doi:10.1186/s40478-018-0543-z. http://dx.doi.org/10.1186/s40478-018-0543-z.

Abstract

Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer’s Disease (AD). By interrogating IgG+ memory B cells from asymptomatic donors with tau peptides, we have identified two somatically mutated VH5–51/VL4–1 antibodies. One of these, CBTAU-27.1, binds to the aggregation motif in the R3 repeat domain and blocks the aggregation of tau into paired helical filaments (PHFs) by sequestering monomeric tau. The other, CBTAU-28.1, binds to the N-terminal insert region and inhibits the spreading of tau seeds and mediates the uptake of tau aggregates into microglia by binding PHFs. Crystal structures revealed that the combination of VH5–51 and VL4–1 recognizes a common Pro-Xn-Lys motif driven by germline-encoded hotspot interactions while the specificity and thereby functionality of the antibodies are defined by the CDR3 regions. Affinity improvement led to improvement in functionality, identifying their epitopes as new targets for therapy and prevention of AD. Electronic supplementary material The online version of this article (10.1186/s40478-018-0543-z) contains supplementary material, which is available to authorized users.

Description

Research Data

Keywords

Alzheimer’s disease, Tau protein, Monoclonal antibody, Antigenic motif

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories